Early and tight glycaemic control: The key to managing type 2 diabetes

Australian Family Physician

Volumn 41, Issue 9, 2012, Pages 681-684

  Deed, Gary ^a   Barlow, John ^b   Kuo, Ivan ^c  

^a Diabetes Specific Interest Group of the RACGP   (Australia)

^b Nepean Hospital ^*

^c NEPEAN HOSPITAL   (Australia)

Author keywords

Diabetes mellitus, type 2; Glycosylated; Hemoglobin A

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; METFORMIN;

ARTICLE; AUSTRALIA; CLINICAL PRACTICE; DISEASE COURSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

AUSTRALIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84867675039     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Australian Institute of Health and Welfare. Diabetes: Australian facts 2008. Diabetes series no. 8. Cat no. CVD 40. Canberra: AIHW, 2008.
2. Davis WA, Knuiman MW, Hendrie D, Davis TM. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. Intern Med J 2006;36:155-61.
3. Jiwa M, Meng X, Sriram D, et al. The management of type 2 diabetes: a survey of Australian general practitioners. Diabetes Res Clin Pract 2012;95:326- 32.
4. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59:1345-55.
5. M acisaac RJ, Jerums G, Weekes AJ, Thomas MC. Patterns of glycaemic control in Australian primary care (NEFRON 8). Intern Med J 2009;39:512-8.
6. Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70:90-7.
7. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34.
8. Davis TM, Davis Cyllene Uwa Edu Au WA, Bruce DG. Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Med J Aust 2006;184:325-8.
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
11. N athan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
12. Kerr D, Partridge H, Knott J, Thomas PW. HbA(1c) 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabet Med 2011;28:1520-4.
13. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
14. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
15. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28.
16. Cheung NW, Conn JJ, d'Emden MC, et al. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust 2009;191:339-44.